Conditional reachability of uncertain Max Plus Linear systems

The reachability analysis problem of Max Plus Linear (MPL) systems has been properly solved using the Difference-Bound Matrices approach. In this work, the same approach is considered in order to solve the reachability analysis problem of MPL systems subjected to bounded noise, disturbances and/or modeling errors, called uncertain MPL (uMPL) systems. Moreover, using the results on the reachability analysis of uMPL systems, we solve the conditional reachability problem, herein defined as the support calculation of the probability density function involved in the stochastic filtering problem

MinMaxGDJS : A WEB Toolbox to handle pseudo-periodic series in MinMax[[gamma,delta]]

Timed Event Graphs (TEGs) constitue an important class of Discrete Event Systems that have a wide domain of applicability. Analysing the temporal behavior of these systems has proven to be efficient, primarily through the use of max-plus algebra and more particularly with formal series of MinMax[[gamma,delta]] semiring. We present, MinMaxGDJS, a web toolbox to handle formal series in MinMax[[gamma,delta]] semiring. Making the library accessible on the web makes it easier to experiment and calculus with formal series without the overhead of configuring and building the C++ library. Web browsers become an excellent platform for giving portable demos

Elastase-2, a tissue alternative pathway for angiotensin II generation, plays a role in circulatory sympathovagal balance in mice

In vitro and ex vivo experiments indicate that elastase-2 (ELA-2), a chymotrypsin-serine protease elastase family member 2A, is an alternative pathway for angiotensin II (Ang II) generation. However, the role played by ELA-2 in vivo is unclear. We examined ELA-2 knockout (ELA-2KO) mice compared to wild-type (WT) mice and determined whether ELA-2 played a role in hemodynamics [arterial pressure (AP) and heart rate (HR)], cardiocirculatory sympathovagal balance and baroreflex sensitivity. The variability of systolic arterial pressure (SAP) and pulse interval (PI) for evaluating autonomic modulation was examined for time and frequency domains (spectral analysis), whereas a symbolic analysis was also used to evaluate PI variability. In addition, baroreflex sensitivity was examined using the sequence method. Cardiac function was evaluated echocardiographically under anesthesia. The AP was normal whereas the HR was reduced in ELA-2KO mice (425 ± 17 vs. 512 ± 13 bpm from WT). SAP variability and baroreflex sensitivity were similar in both strains. The LF power from the PI spectrum (33.6 ± 5 vs. 51.8 ± 4.8 nu from WT) and the LF/HF ratio (0.60 ± 0.1 vs. 1.45 ± 0.3 from WT) were reduced, whereas the HF power was increased (66.4 ± 5 vs. 48.2 ± 4.8 nu from WT) in ELA-2KO mice, indicating a shift toward parasympathetic modulation of HR. Echocardiographic examination showed normal fractional shortening and an ejection fraction in ELA-2KO mice; however, the cardiac output, stroke volume, and ventricular size were reduced. These findings provide the first evidence that ELA-2 acts on the sympathovagal balance of the heart, as expressed by the reduced sympathetic modulation of HR in ELA-2KO mice

Transitions of cardio-metabolic risk factors in the Americas between 1980 and 2014

Describing the prevalence and trends of cardiometabolic risk factors that are associated with non-communicable diseases (NCDs) is crucial for monitoring progress, planning prevention, and providing evidence to support policy efforts. We aimed to analyse the transition in body-mass index (BMI), obesity, blood pressure, raised blood pressure, and diabetes in the Americas, between 1980 and 2014

A century of trends in adult human height

Being taller is associated with enhanced longevity, and higher education and earnings. We reanalysed 1472 population-based studies, with measurement of height on more than 18.6 million participants to estimate mean height for people born between 1896 and 1996 in 200 countries. The largest gain in adult height over the past century has occurred in South Korean women and Iranian men, who became 20.2 cm (95% credible interval 17.5-22.7) and 16.5 cm (13.3-19.7) taller, respectively. In contrast, there was little change in adult height in some sub-Saharan African countries and in South Asia over the century of analysis. The tallest people over these 100 years are men born in the Netherlands in the last quarter of 20th century, whose average heights surpassed 182.5 cm, and the shortest were women born in Guatemala in 1896 (140.3 cm; 135.8-144.8). The height differential between the tallest and shortest populations was 19-20 cm a century ago, and has remained the same for women and increased for men a century later despite substantial changes in the ranking of countries

Antiangiogenic And Finasteride Therapies: Responses Of The Prostate Microenvironment In Elderly Mice

Aims The aim of this study was to evaluate the structural and molecular effects of antiangiogenic therapies and finasteride on the ventral prostate of senile mice. Main methods 90 male FVB mice were divided into: Young (18 weeks old) and senile (52 weeks old) groups; finasteride group: finasteride (20 mg/kg); SU5416 group: SU5416 (6 mg/kg); TNP-470 group: TNP-470 (15 mg/kg,) and SU5416 + TNP-470 group: similar to the SU5416 and TNP-470 groups. After 21 days, prostate ventral lobes were collected for morphological, immunohistochemical and Western blotting analyses. Key findings The results demonstrated atrophy, occasional proliferative lesions and inflammatory cells in the prostate during senescence, which were interrupted and/or blocked by treatment with antiangiogenic drugs and finasteride. Decreased AR and endostatin reactivities, and an increase for ER-α, ER-β and VEGF, were seen in the senile group. Decreased VEGF and ER-α reactivities and increased ER-β reactivity were verified in the finasteride, SU5416 groups and especially in SU5416 + TNP-470 group. The TNP-470 group showed reduced AR and ER-β protein levels. Significance The senescence favored the occurrence of structural and/or molecular alterations suggesting the onset of malignant lesions, due to the imbalance in the signaling between the epithelium and stroma. The SU5416 + TNP-470 treatment was more effective in maintaining the structural, hormonal and angiogenic factor balance in the prostate during senescence, highlighting the signaling of antiproliferation via ER-β. © 2014 Elsevier Inc.10601/02/155870Abdollahi, A., Lipson, K.E., Sckell, A., Zieher, H., Klenke, F., Poerschke, D., Roth, A., Huber, P.E., Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects (2003) Cancer Research, 63 (24), pp. 8890-8898Amikura, K., Matsuno, S., Egawa, S., Synergistic antitumor effect of an angiogenesis inhibitor (TNP-470) and tumor necrosis factor in mice (2006) Surgery Today, 36 (12), pp. 1069-1074. , DOI 10.1007/s00595-006-3289-3Andreollo, N.A., Santos, E.F., Araújo, M.R., Lopes, L.R., Rat's age versus human's age: What is the relationship? (2012) Arq Bras Cir Dig, 25 (1), pp. 49-51Aragon-Ching, J.B., Madan, R.A., Dahut, W.L., Angiogenesis inhibition in prostate cancer: Current uses and future promises (2010) J Oncol, 1-7Ban, H.S., Uno, M., Nakamura, H., Suppression of hypoxia-induced HIF-1alpha accumulation by VEGF inhibitors: Different profiles of AAL993 versus SU5416 and KRN633 (2010) Cancer Lett, 296 (1), pp. 17-26Banerjee, S., Banerjee, P.P., Brown, T.R., Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age (2000) Endocrinology, 141 (2), pp. 821-832. , DOI 10.1210/en.141.2.821Bavik, C., Coleman, I., Dean, J.P., Knudsen, B., Plymate, S., Nelson, P.S., The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms (2006) Cancer Research, 66 (2), pp. 794-802. , DOI 10.1158/0008-5472.CAN-05-1716Bianchi-Frias, D., Vakar-Lopez, F., Coleman, I.M., Plymate, S.R., Reed, M.J., Nelson, P.S., The effects of aging on the molecular and cellular composition of the prostate microenvironment (2010) PLoS One, 5 (9), pp. 1-16Bruni-Cardoso, A., Augusto, T.M., Pravatta, H., Damas-Souza, D.M., Carvalho, H.F., Stromal remodelling is required for progressive involution of the rat ventral prostate after castration: Identification of a matrix metalloproteinase-dependent apoptotic wave (2010) Int J Androl, 33 (5), pp. 686-695Cai, J., Hong, Y., Weng, C., Tan, C., Imperato-Mcginley, J., Zhu, Y.-S., Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism (2011) Am J Physiol Heart Circ Physiol, 300, pp. 1210-H1221Candido, E.M., Fávaro, W.J., Montico, F., Hetzl, A.C., Cagnon, V.H.A., Senescence and steroid hormone receptor reactivities in accessory sex glands of elderly rats (Sprague-Dawley) following exogenous hormonal therapy (2012) Tissue Cell, 44 (4), pp. 227-237Castronovo, V., Belotti, D., TNP-470 mechanisms of action and early clinical development (1996) EJC, 32 (14), pp. 2520-2527Chang, B.-D., Broude, E.V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E.S., Roninson, I.B., A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents (1999) Cancer Research, 59 (15), pp. 3761-3767Cheng, L., Zhang, S., Sweeney, C.J., Kao, C., Gardner, T.A., Eble, J.N., Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model (2004) Anticancer Research, 24 (4), pp. 2135-2140Christensen, J.G., A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities (2007) Ann Oncol, 18, pp. 3-x10Cordeiro, R.S., Scarano, W.R., Campos, S.G., Santos, F.C., Vilamaior, P.S., Góes, R.M., Androgen receptor in the Mongolian gerbil ventral prostate: Evaluation during different phases of postnatal development and following androgen blockage (2008) Micron, 39 (8), pp. 1312-1324Crawford, E.D., Andriole, G.L., Marberger, M., Rittmaster, R.S., Reduction in the risk of prostate cancer: Future directions after the Prostate Cancer Prevention Trial (2010) Urology, 75 (3), pp. 502-509Cunha, G.R., Hayward, S.W., Wang, Y.Z., Role of stroma in carcinogenesis of the prostate (2002) Differentiation, 70 (9-10), pp. 473-485. , DOI 10.1046/j.1432-0436.2002.700902.xDavalos, A.R., Coppe, J.-P., Campisi, J., Desprez, P.-Y., Senescent cells as a source of inflammatory factors for tumor progression (2010) Cancer Metastasis Rev, 29 (2), pp. 273-283Delongchamps, N.B., Peyromaure, M., Dinh-Xuan, A.T., Role of vascular endothelial growth factor in prostate cancer (2006) Urology, 68 (2), pp. 244-248. , DOI 10.1016/j.urology.2006.03.010, PII S0090429506003542Ellem, S.J., Risbridger, G.P., The dual, opposing roles of estrogen in the prostate (2009) Ann N y Acad Sci, 1155, pp. 174-186Ellem, S.J., Risbridger, G.P., Aromatase and regulating the estrogen: Androgen ratio in the prostate gland (2010) J Steroid Biochem Mol Biol, 118, pp. 246-251Folkman, J., Antiangiogenesis in cancer therapy: Endostatin and its mechanisms of action (2005) Exp Cell Res, 312, pp. 594-606Folkman, J., Hahnfeldt, P., Hlatky, L., The logic of anti-angiogenic gene therapy (1998) The Development of Gene Therapy, pp. 527-543. , T. Friedmann, Cold Spring Harbor Laboratory Press New YorkFong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., McMahon, G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types (1999) Cancer Research, 59 (1), pp. 99-106Glassman, D.T., Chon, J.K., Borkowski, A., Jacobs, S.C., Kyprianou, N., Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-β expression in benign prostatic hyperplasia (2001) Prostate, 46 (1), pp. 45-51. , DOI 10.1002/1097-0045(200101)46:1<45::AID-PROS1007>3.0.CO;2-UGonzales, G.F., Gasco, M., Malheiros-Pereira, A., Gonzales-Castaneda, C., Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice (2008) Andrologia, 40 (3), pp. 179-185. , DOI 10.1111/j.1439-0272.2008.00834.xHäggström, S., Stattin, P., Wikström, P., Bergh, A., Damber, J.E., Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer (2001) BJU Int, 88 (1), pp. 110-116Hetzl, A.C., Montico, F., Lorencini, R.M., Kido, L.A., Cândido, E.M., Cagnon, V.H., Prostatic microenvironment in senescence: Fibroblastic growth factors × hormonal imbalance (2013) Histochem Cell Biol, , 10.1007/s00418-013-1173-yHochberg, D.A., Basillote, J.B., Armenakas, N.A., Vasovic, L., Shevchuk, M., Pareek, G., Fracchia, J.A., Decreased suburethral prostatic microvessel density in finasteride treated prostates: A possible mechanism for reduced bleeding in benign prostatic hyperplasia (2002) Journal of Urology, 167 (4), pp. 1731-1733Hsing, A.W., Hormones and prostate cancer: What's next? (2001) Epidemiologic Reviews, 23 (1), pp. 42-58Huss, W.J., Barrios, R.J., Greenberg, N.M., SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis (2003) Mol Cancer Ther, 2, pp. 611-616Justulin, L.A., Della-Coleta, H.H.M., Taboga, S.R., Felisbino, S.L., Matrix metalloproteinase MMP-2 and MMP-9 activity and localization during ventral prostate atrophy and regrowth (2010) Int J Androl, 33 (5), pp. 696-708Kato, T., Sato, K., Kakinuma, H., Matsuda, Y., Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice (1994) Cancer Research, 54 (19), pp. 5143-5147Krtolica, A., Campisi, J., Cancer and aging: A model for the cancer promoting effects of the aging stroma (2002) International Journal of Biochemistry and Cell Biology, 34 (11), pp. 1401-1414. , DOI 10.1016/S1357-2725(02)00053-5, PII S1357272502000535Lau, K.-M., Tam, N.N.C., Thompson, C., Cheng, R.Y.S., Leung, Y.-K., Ho, S.-M., Age-associated changes in histology and gene-expression profile in the rat ventral prostate (2003) Laboratory Investigation, 83 (5), pp. 743-757Franck-Lissbrant, I., Haggstrom, S., Damber, J.-E., Bergh, A., Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats (1998) Endocrinology, 139 (2), pp. 451-456. , DOI 10.1210/en.139.2.451Lissbrant, I.F., Hammarsten, P., Lissbrant, E., Ferrara, N., Rudolfsson, S.H., Bergh, A., Neutralizing VEGF Bioactivity with a Soluble Chimeric VEGF-Receptor Protein flt(I-3) IgG Inhibits Testosterone-Stimulated Prostate Growth in Castrated Mice (2004) Prostate, 58 (1), pp. 57-65. , DOI 10.1002/pros.10312Lohmiller, Swing, The laboratory rat (2005) Reproduction and Breeding, pp. 147-164. , Academic Press [Imprint, Charpter 6]Lucia, M.S., Epstein, J.I., Goodman, P.J., Darke, A.K., Reuter, V.E., Civantos, F., Tangen, C.M., Thompson, I.M., Finasteride and high-grade prostate cancer in the prostate cancer prevention trial (2007) Journal of the National Cancer Institute, 99 (18), pp. 1375-1383. , DOI 10.1093/jnci/djm117Masiero, L., Figg, W.D., Kohn, E.C., New anti-angiogenesis agents: Review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12 (1997) Angiogenesis, 1 (1), pp. 23-35Matsusaka, S., Nakasho, K., Terada, N., Sugihara, A., Tsujimura, T., Takanashi, T., Uematsu, K., Toyosaka, A., Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice (2000) Journal of Pediatric Surgery, 35 (8), pp. 1198-1204. , DOI 10.1053/jpsu.2000.8726Miki, T., Nonomura, N., Nozawa, M., Harada, Y., Nishimura, K., Kojima, Y., Takahara, S., Okuyama, A., Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line (1998) Journal of Urology, 160 (1), pp. 210-213. , DOI 10.1016/S0022-5347(01)63092-1Montico, F., Hetzl, A.C., Cândido, E.M., Fávaro, W.J., Cagnon, V.H.A., Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules (2011) Micron, 42 (6), pp. 642-655Morales, A., Androgen replacement therapy and prostate safety (2002) European Urology, 41 (2), pp. 113-120. , DOI 10.1016/S0302-2838(01)00039-2, PII S0302283801000392Nickel, J.C., True, L.D., Krieger, J.N., Berger, R.E., Boag, A.H., Young, I.D., Consensus development of a histopathological classification system for chronic prostatic inflammation (2001) BJU International, 87 (9), pp. 797-805. , DOI 10.1046/j.1464-410X.2001.02193.xO'Donnell, L., Robertson, K.M., Jones, M.E., Simpson, E.R., Estrogen and spermatogenesis (2001) Endocrine Reviews, 22 (3), pp. 289-318. , DOI 10.1210/er.22.3.289Pareek, G., Shevchuk, M., Armenakas, N.A., Vasjovic, L., Hochberg, D.A., Basillote, J.B., Fracchia, J.A., The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients (2003) Journal of Urology, 169 (1), pp. 20-23Pelletier, G., El-Alfy, M., Immunocytochemical localization of estrogen receptors α and β in the human reproductive organs (2000) Journal of Clinical Endocrinology and Metabolism, 85 (12), pp. 4835-4840. , DOI 10.1210/jc.85.12.4835Quinn, R., Comparing rat's to human's age: How old is my rat in people years? (2005) Nutrition, 21 (6), pp. 775-777. , DOI 10.1016/j.nut.2005.04.002, PII S0899900705001711Reed, M.J., Karres, N., Eyman, D., Cruz, A., Brekken, R.A., Plymate, S., The effects of aging on tumor growth and angiogenesis are tumor-cell dependent (2007) International Journal of Cancer, 120 (4), pp. 753-760. , DOI 10.1002/ijc.22351Reynolds, A.R., Kaprianou, N., Growth factor signaling in prostatic growth: Significance in tumor development and therapeutic targeting (2006) Br J Pharmacol, 147, pp. 144-S152Rittmaster, R.S., Manning, A.P., Wright, A.S., Thomas, L.N., Whitefield, S., Norman, R.W., Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride (1995) Endocrinology, 136 (2), pp. 741-748Roy-Burman, P., Wu, H., Powell, W.C., Hagenkord, J., Cohen, M.B., Genetically defined mouse models that mimic natural aspects of human prostate cancer development (2004) Endocrine-Related Cancer, 11 (2), pp. 225-254. , DOI 10.1677/erc.0.0110225Sim, B.K.L., MacDonald, N.J., Gubish, E.R., Angiostatin and endostatin: Endogenous inhibitors of tumor growth (2000) Cancer and Metastasis Reviews, 19 (1-2), pp. 181-190. , DOI 10.1023/A:1026551202548Strieth, S., Eichhorn, M.E., Sutter, A., Jonczyk, A., Berghaus, A., Dellian, M., Antiangiogenic combination tumor therapy blocking alpha (v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo (2006) Int J Cancer, 119 (2), pp. 423-431Thompson, I.M., Lucia, M.S., Redman, M.W., Darke, A., La Rosa, F.G., Parnes, H.L., Finasteride decreases the risk of prostatic intraepithelial neoplasia (2007) J Urol, 178 (1), pp. 107-109Thompson, I.M., Tangen, C.M., Goodman, P.J., Lucia, M.S., Klein, E.A., Chemoprevention of prostate cancer (2009) J Urol, 182 (2), pp. 499-507Tomas, D., Kruslin, B., The potential value of (myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma (2004) Prostate, 61 (4), pp. 324-331. , DOI 10.1002/pros.20109Toorians, A.W.F.T., Kelleher, S., Gooren, L.J., Jimenez, M., Handelsman, D.J., Estimating the Contribution of the Prostate to Blood Dihydrotestosterone (2003) Journal of Clinical Endocrinology and Metabolism, 88 (11), pp. 5207-5211. , DOI 10.1210/jc.2003-030521Tutrone, Jr.R.F., Ball, R.A., Ornitz, D.M., Leder, P., Richie, J.P., Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model (1993) J Urol, 149 (3), pp. 633-699Tuxhorn, J.A., Ayala, G.E., Smith, M.J., Smith, V.C., Dang, T.D., Rowley, D.R., Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling (2002) Clinical Cancer Research, 8 (9), pp. 2912-2923Tuxhorn, J.A., McAlhany, S.J., Dang, T.D., Ayala, G.E., Rowley, D.R., Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model (2002) Cancer Research, 62 (11), pp. 3298-3307Van Moorselaar, R.J.A., Voest, E.E., Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches (2002) Molecular and Cellular Endocrinology, 197 (1-2), pp. 239-250. , DOI 10.1016/S0303-7207(02)00262-9, PII S0303720702002629Weidner, N., Carroll, P.R., Flax, J., Blumenfeld, W., Folkman, J., Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma (1993) American Journal of Pathology, 143 (2), pp. 401-409Weihua, Z., Makela, S., Andersson, L.C., Salmi, S., Saji, S., Webster, J.I., Jensen, E.V., Gustafsson, J.-A., A role for estrogen receptor β in the regulation of growth of the ventral prostate (2001) Proceedings of the National Academy of Sciences of the United States of America, 98 (11), pp. 6330-6335. , DOI 10.1073/pnas.111150898Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., Fujita, T., Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470AGM- 1470) (1993) Cancer Research, 53 (18), pp. 4262-4267Zar, J.H., (1999) Biostatistical Analysis, , 4th ed. Prentice Hall Upper, New JerseyZhao, H., Patra, A., Yeh, C.-C., Tanaka, Y., Oh, B.R., Dahiya, R., Effects of aging on growth factors gene and protein expression in the dorsal and ventral lobes of rat prostate (2002) Biochemical and Biophysical Research Communications, 292 (2), pp. 482-491. , DOI 10.1006/bbrc.2002.6660Zhong, X.-S., Zheng, J.Z., Reed, E., Jiang, B.-H., SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway (2004) Biochemical and Biophysical Research Communications, 324 (2), pp. 471-480. , DOI 10.1016/j.bbrc.2004.09.082, PII S0006291X0402116

Prostatic Microenvironment In Senescence: Fibroblastic Growth Factors X Hormonal Imbalance

The aim was to characterize and correlate steroid hormone receptors with the FGF2, FGF7 and FGF8 reactivities in the prostatic epithelium and stroma in senile rats. Fifty male senile rats and 10 young male rats were divided into the young (YNG), the senile groups (SE), the castrated group (CAS), the estrogen-deficient group (ED), the castrated + estrogen group (CASE), and the estrogen-deficient + androgen group (EDTEST). The ventral prostate was submitted to immunohistochemical and Western blotting analyses. The results showed decreased AR and ERβ levels and increased ERα in the senile animals in relation to YNG group. Increased ERα and ERβ reactivities presenting differential localization were characterized in the CASE group compared to the CAS group. Increased FGF2 level was observed in the stroma of the CAS and ED groups in relation to the SE group and in the epithelium of the ED group in relation to the other groups. Increased and differential immunolocalization of FGF7 levels were observed in the CAS, ED and CASE groups. The FGF8 levels showed differential localization in the CAS and ED groups compared to the senile group. The intense hormone ablation was favorable to the autocrine signaling of FGF2 and FGF8. FGF7 could be activated in the androgen-independent via considering the increased FGF7 in the castrated rats. We concluded that hormone ablation in senescence was favorable to activation or/and to fibroblast signaling in the prostatic microenvironment. © 2013 Springer-Verlag.1415531542Banerjee, S., Banerjee, P.P., Brown, T.R., Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age (2000) Endocrinology, 141, pp. 821-822Banerjee, P.P., Banerjee, S., Brown, T.R., Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the Brown Norway rat prostate (2001) Endocrinology, 142 (9), pp. 4066-4075. , DOI 10.1210/en.142.9.4066Carruba, G., Estrogens and mechanisms of prostate cancer progression (2006) Ann N Y Acad Sci, 1089, pp. 201-217Cordeiro, R.S., Scarano, W.R., Campos, S.G., Santos, F.C., Vilamaior, P.S., Góes, R.M., Taboga, S.R., Androgen receptor in the Mongolian gerbil ventral prostate: Evaluation during different phases of postnatal development and following androgen blockage (2008) Micron, 39, pp. 1312-1324Cotton, L.M., O'Bryan, M.K., Hinton, B.T., Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction (2008) Endocr Rev, 29, pp. 193-216Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., Klocker, H., Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor (1994) Cancer Res, 54, pp. 5474-5478Dorkin, T.J., Robinson, M.C., Marsh, C., Bjartell, A., Neal, D.E., Leung, H.Y., FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease (1999) Oncogene, 18 (17), pp. 2755-2761. , DOI 10.1038/sj.onc.1202624Ellem, S.J., Risbridger, G.P., The dual, opposing roles of estrogen in the prostate (2009) Ann N Y Acad Sci, 1155, pp. 174-186Gao, J., Arnold, J.T., Isaacs, J.T., Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells (2001) Cancer Research, 61 (13), pp. 5038-5044Gnanapragasam, V.J., Robinson, M.C., Marsh, C., Robson, C.N., Hamdy, F.C., Leung, H.Y., FGF8 isoform b expression in human prostate cancer (2003) British Journal of Cancer, 88 (9), pp. 1432-1438. , DOI 10.1038/sj.bjc.6600875Heer, R., Collins, A.T., Robson, C.N., Shenton, B.K., Leung, H.Y., KGF suppresses α2β1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium (2006) J Cell Sci, 119, pp. 1416-1424Hetzl, A.C., Montico, F., Lorencini, R.M., Kido, L., Candido, M., Billis, A., Ferreira, U., Cagnon, V.H.A., Fibroblast growth factor, estrogen and prolactin receptor features in different grades of prostatic adenocarcinoma in elderly men (2013) Microsc Res Tech, 76, pp. 321-330Huss, W.J., Barrios, R.J., Foster, B.A., Greenberg, N.M., Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression (2003) Prostate, 54 (1), pp. 8-16. , DOI 10.1002/pros.10163Ishii, K., Mizokami, A., Tsunoda, T., Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells (2011) J Cell Biochem, 112, pp. 3604-3611Krieg, M., Nass, R., Tunn, S., Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate (1993) Journal of Clinical Endocrinology and Metabolism, 77 (2), pp. 375-381. , DOI 10.1210/jc.77.2.375Kwabi-Addo, B., Ozen, M., Ittmann, M., The role of fibroblast growth factors and their receptors in prostate cancer (2004) Endocrine-Related Cancer, 11 (4), pp. 709-724. , DOI 10.1677/erc.1.00535Lanner, F., Rossant, J., The role of FGF/Erk signaling in pluripotent cells (2010) Development, 137, pp. 3351-3360Latil, A., Bieche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., Vidaud, M., Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays (2001) Cancer Research, 61 (5), pp. 1919-1926Lin, Y., Liu, G., Zhang, Y., Hu, Y.-P., Yu, K., Lin, C., McKeehan, K., Wang, F., Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis (2007) Development, 134 (4), pp. 723-734. , DOI 10.1242/dev.02765Morales, A., Androgen replacement therapy and prostate safety (2002) Eur Urol, 41, pp. 113-120Morrissey, C., Buser, A., Scolaro, J., O'Sullivan, J., Moquin, A., Tenniswood, M., Changes in hormone sensitivity in the ventral prostate of aging Sprague-Dawley rats (2002) Journal of Andrology, 23 (3), pp. 341-351Nemeth, J.A., Zelner, D.J., Lang, S., Lee, C., Keratinocyte growth factor in the rat ventral prostate: Androgen- independent expression (1998) Journal of Endocrinology, 156 (1), pp. 115-125. , DOI 10.1677/joe.0.1560115Planz, B., Wang, Q., Kirley, S.D., Lin, C.-W., Mcdougal, W.S., Androgen responsiveness of stromal cells of the human prostate: Regulation of cell proliferation and keratinocyte growth factor by androgen (1998) Journal of Urology, 160 (5), pp. 1850-1855Prins, G.S., Birch, L., Couse, J.F., Choi, I., Katzenellenbogen, B., Korach, K.S., Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with αERKO and βERKO mice (2001) Cancer Research, 61 (16), pp. 6089-6097Roy-Burman, P., Wu, H., Powell, W.C., Hagenkord, J., Cohen, M.B., Genetically defined mouse models that mimic natural aspects of human prostate cancer development (2004) Endocrine-Related Cancer, 11 (2), pp. 225-254. , DOI 10.1677/erc.0.0110225Sattolo, S., Carvalho, C.A.F., Cagnon, V.H.A., Influence of hormonal replacement on the ventral lobe of the prostate of rats (Rattus norvegicus albinus) submitted to chronic ethanol treatment (2004) Tissue and Cell, 36 (6), pp. 417-430. , DOI 10.1016/j.tice.2004.07.004, PII S0040816604000588Scarano, W.R., Vilamaior, P.S.L., Taboga, S.R., Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate (2006) Anatomical Record - Part A Discoveries in Molecular, Cellular, and Evolutionary Biology, 288 (11), pp. 1190-1200. , DOI 10.1002/ar.a.20391Schwertfeger, K., Fibroblast growth factors in development and cancer: Insights for the mammary and prostate glands (2009) Curr Drug Targets, 10, pp. 632-644Shin, J.-H., Kim, H.S., Moon, H.J., Kang, I.H., Kim, T.S., Seok, J.H., Kim, I.Y., Nam, S.Y., Effects of flutamide on puberty in male rats: An evaluation of the protocol for the assessment of pubertal development and thyroid function (2002) Journal of Toxicology and Environmental Health - Part A, 65 (5-6), pp. 433-445. , DOI 10.1080/15287390252808091Smith, P., Rhodes, N.P., Foster, C.S., Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol (2002) Prostate Cancer and Prostatic Diseases, 5 (2), pp. 105-110. , DOI 10.1038/sj.pcan.4500571Tilley, W.D., Horsfall, D.J., McGee, M.A., Effects of ageing and hormonal manipulations on the level of oestrogen receptors in the guinea-pig prostate (1987) Journal of Endocrinology, 112 (1), pp. 139-144Tobin, V.A., Canny, B.J., The regulation of gonadotropin-releasing hormone-induced calcium signals in male rat gonadotrophs by testosterone is mediated by dihydrotestosterone (1998) Endocrinology, 139 (3), pp. 1038-1045. , DOI 10.1210/en.139.3.1038Tomas, D., Kruslin, B., The potential value of (myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma (2004) Prostate, 61 (4), pp. 324-331. , DOI 10.1002/pros.20109Valta, M.P., Tuomela, J., Bjartell, A., Valve, E., Vaananen, H.K., Harkonen, P., FGF-8 is involved in bone metastasis of prostate cancer (2008) International Journal of Cancer, 123 (1), pp. 22-31. , DOI 10.1002/ijc.23422Wesche, J., Hagund, K., Haugsten, E.M., Fibroblast growth factors and their receptors in cancer (2011) Biochem J, 437, pp. 199-213Yang, F., Strand, D.W., Rowley, D.R., Fibroblast growth factor-2 mediates transforming growth factor-â action in prostate cancer reactive stroma TGF-â signaling in prostate cancer reactive stroma (2008) Oncogene, 27, pp. 450-459Zar, J.H., (1999) Bioestatistical Analysis, , 4t edn. Prentice Hall Upper, New Jerse

Antiangiogenic Therapy Effects On Age-associated Matrix Metalloproteinase-9 (mmp-9) And Insulin-like Growth Factor Receptor-1 (igfr-1) Responses: A Comparative Study Of Prostate Disorders In Aged And Tramp Mice

Senescence is associated with hormonal imbalance and prostatic disorders. Angiogenesis is fundamental for the progression of malignant lesions and is a promising target for prostate cancer treatment. The aim was to characterize matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses in the prostate during senescence and following antiangiogenic and/or androgen ablation therapies, comparing them to cancer progression features in TRAMP mice. Aged male mice (52-week-old FVB) were submitted to antiangiogenic treatments with SU5416 (6 mg/kg; i.p.) and/or TNP-470 (15 mg/kg; s.c). Finasteride (20 mg/kg; s.c.) was administered alone or associated to both inhibitors. Dorsolateral prostate was collected for light microscopy, and immunohistochemistry and Western blotting collected for MMP-9 and IGFR-1. Senescence led to inflammation and different proliferative lesions in the prostate, as well as to increased MMP-9 and IGFR-1, resembling TRAMP mice prostatic microenvironment. Antiangiogenic therapies promoted recovery and/or interruption of age-associated alterations, presenting differential effects on the molecules studied. SU5416 acted mainly on MMP-9, whereas TNP-470 showed its best influence on IGFR-1 levels. Finasteride administration, alone or in combination with antiangiogenic agents, also resulted in regression of inflammation and neoplastic lesions, besides having a negative modulatory effect on both MMP-9 and IGFR-1. We concluded that stimulated tissue remodeling and proliferative processes during senescence predisposed the prostate to malignant disorders. The combination of different agents was more effective to minimize prostatic imbalance during this period, probably due to the differential action of each drug on factors involved in cell proliferation and extracellular matrix remodeling, resulting in a broader spectrum of effects following the combined treatment. © 2014 Springer-Verlag.1423269284Abdollahi, A., Lipson, K.E., Sckell, A., Zieher, H., Klenke, F., Poerschke, D., Roth, A., Huber, P.E., Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects (2003) Cancer Research, 63 (24), pp. 8890-8898Anawalt, B.D., Merriam, G.R., Neuroendocrine aging in men: Andropause and somatopause (2001) Endocrinology and Metabolism Clinics of North America, 30 (3), pp. 647-669. , DOI 10.1016/S0889-8529(05)70206-1Aragon-Ching, J.B., Dahut, W.L., VEGF inhibitors and prostate cancer therapy (2009) Curr Mol Pharmacol, 2, pp. 161-168Bandyopadhyay, A., Wang, L., Lopez-Casillas, F., Mendoza, V., Yeh, I.-T., Sun, L., Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer (2005) Prostate, 63 (1), pp. 81-90. , DOI 10.1002/pros.20166Banerjee, P.P., Banerjee, S., Lai, J.M., Strandberg, J.D., Zirkin, B.R., Brown, T.R., Age-dependent and lobe-specific spontaneous hyperplasia in the Brown Norway rat prostate (1998) Biology of Reproduction, 59 (5), pp. 1163-1170. , DOI 10.1095/biolreprod59.5.1163Banerjee, P.P., Banerjee, S., Brown, T.R., Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the Brown Norway rat prostate (2001) Endocrinology, 142 (9), pp. 4066-4075. , DOI 10.1210/en.142.9.4066Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Hanahan, D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) Nat Cell Biol, 2, pp. 737-744Berman-Booty, L.D., Sargeant, A.M., Rosol, T.J., Rengel, R.C., Clinton, S.K., Chen, C.S., Kulp, S.K., A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice (2012) Toxicol Pathol, 40, pp. 5-17Bianchi-Frias, D., Vakar-Lopez, F., Coleman, I.M., Plymate, S.R., Reed, M.J., Nelson, P.S., The effects of aging on the molecular and cellular composition of the prostate microenvironment (2010) PLoS ONE, , doi:10.1371/journal.pone.0012501Bosland, M.C., Animal models for the study of prostate carcinogenesis (1992) J Cell Biochem Suppl, 16, pp. 89-98Campisi, J., Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors (2005) Cell, 120, pp. 513-522Castronovo, V., Belotti, D., TNP-470 (AGM-1470): Mechanisms of action and early clinical development (1996) Eur J Cancer, 32, pp. 2520-2527Condon, M.S., The role of the stromal microenvironment in prostate cancer (2005) Semin Cancer Biol, 15, pp. 132-137Coppé, J.P., Kauser, K., Campisi, J., Beauséjour, C.M., Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence (2006) J Biol Chem, 281, pp. 29568-29574Cordeiro, R.S., Scarano, W.R., Campos, S.G., Santos, F.C., Vilamaior, P.S., Góes, R.M., Taboga, S.R., Androgen receptor in the Mongolian gerbil ventral prostate: Evaluation during different phases of postnatal development and following androgen blockage (2008) Micron, 39, pp. 1312-1324Delella, F.K., Justulin Jr., L.A., Felisbino, S.L., Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate (2010) Int J Androl, 33, pp. e114-e122Djavan, B., Waldert, M., Seitz, C., Marberger, M., Insulin-like growth factors and prostate cancer (2001) World Journal of Urology, 19 (4), pp. 225-233Doll, J.A., Reiher, F.K., Crawford, S.E., Pins, M.R., Campbell, S.C., Bouck, N.P., Thrombospondin-I, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate (2001) Prostate, 49 (4), pp. 293-305. , DOI 10.1002/pros.10025Ellis, L.M., Takahashi, Y., Liu, W., Shaheen, R.M., Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications (2000) Oncologist, 5 (SUPPL. 1), pp. 11-15Figg, W.D., Kruger, E.A., Price, D.K., Kim, S., Dahut, W.D., Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer (2002) Investigational New Drugs, 20 (2), pp. 183-194. , DOI 10.1023/A:1015626410273Folkman, J., Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action (2006) Exp Cell Res, 312, pp. 594-607Folkman, J.H.P., Hlatky, L., The logic of anti-angiogenic gene therapy (1998) The Development of Gene Therapy, pp. 1-17. , Friedmann T (ed) Cold Spring Harbor Laboratory Press, New YorkFong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., McMahon, G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types (1999) Cancer Research, 59 (1), pp. 99-106Gennigens, C., Menetrier-Caux, C., Droz, J.P., Insulin-like growth factor (IGF) family and prostate cancer (2006) Crit Rev Oncol Hematol, 58, pp. 124-145Gervaz, P., Scholl, B., Padrun, V., Gillet, M., Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470 (2000) Liver, 20 (2), pp. 108-113. , DOI 10.1034/j.1600-0676.2000.020002108.xGingrich, J.R., Barrios, R.J., Foster, B.A., Greenberg, N.M., Pathologic progression of autochthonous prostate cancer in the TRAMP model (1999) Prostate Cancer and Prostatic Diseases, 2 (2), pp. 70-75Gonzales, G.F., Gasco, M., Malheiros-Pereira, A., Gonzales-Castaneda, C., Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice (2008) Andrologia, 40 (3), pp. 179-185. , DOI 10.1111/j.1439-0272.2008.00834.xGreenberg, N.M., Demayo, F., Finegold, M.J., Medina, D., Tilley, W.D., Aspinall, J.O., Cunha, G.R., Rosen, J.M., Prostate cancer in a transgenic mouse (1995) Proc Natl Acad Sci USA, 92, pp. 3439-3443Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., Burfiend, P., Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3 and suppresses MMP-2 expression (2004) Journal of Pathology, 202 (1), pp. 50-59. , DOI 10.1002/path.1492Häggström, S., Torring, N., Moller, K., Jensen, E., Lund, L., Nielsen, J.E., Bergh, A., Damber, J.E., Effects of finasteride on vascular endothelial growth factor (2002) Scand J Urol Nephrol, 36, pp. 182-187Hetzl, A.C., Fávaro, W.J., Billis, A., Ferreira, U., Cagnon, V.H., Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men (2012) Microsc Res Tech, 75, pp. 1197-1205Huss, W.J., Barrios, R.J., Greenberg, N.M., SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis (2003) Mol Cancer Ther, 2, pp. 611-616Huynh, H., Seyam, R.M., Brock, G.B., Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3 (1998) Cancer Research, 58 (2), pp. 215-218Junqueira, L.C.U., Bignolas, G., Brentani, R.R., Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections (1979) Histochemical Journal, 11 (4), pp. 447-455. , DOI 10.1007/BF01002772Kawada, M., Inoue, H., Arakawa, M., Ikeda, D., Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I (2008) Anticancer Research, 28 (2 A), pp. 721-730Kong, D., Li, Y., Wang, Z., Banerjee, S., Sarkar, F.H., Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the NF-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of VEGF in prostate cancer (2007) Cancer Research, 67 (7), pp. 3310-3319. , DOI 10.1158/0008-5472.CAN-06-4277Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kogawa, K., Shioi, A., Morii, H., The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin- like growth factor-I: Possible involvement of cyclin-dependent kinase 2 (1996) Circulation Research, 79 (4), pp. 757-764Krieg, M., Nass, R., Tunn, S., Effect of aging on endogenous level of 5alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate (1993) Journal of Clinical Endocrinology and Metabolism, 77 (2), pp. 375-381. , DOI 10.1210/jc.77.2.375Krtolica, A., Campisi, J., Cancer and aging: A model for the cancer promoting effects of the aging stroma (2002) International Journal of Biochemistry and Cell Biology, 34 (11), pp. 1401-1414. , DOI 10.1016/S1357-2725(02)00053-5, PII S1357272502000535Lau, K.-M., Tam, N.N.C., Thompson, C., Cheng, R.Y.S., Leung, Y.-K., Ho, S.-M., Age-associated changes in histology and gene-expression profile in the rat ventral prostate (2003) Laboratory Investigation, 83 (5), pp. 743-757London, C.A., Sekhon, H.S., Arora, V., Stein, D.A., Iversen, P.L., Devi, G.R., A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity (2003) Cancer Gene Therapy, 10 (11), pp. 823-832. , DOI 10.1038/sj.cgt.7700642Lynch, C.C., Matrisian, L.M., Matrix metalloproteinases in tumor-host cell communication (2002) Differentiation, 70 (9-10), pp. 561-573. , DOI 10.1046/j.1432-0436.2002.700909.xMañes, S., Llorente, M., Lacalle, R.A., Gómez-Moutón, C., Kremer, L., Mira, E., Martinez-A, C., The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells (1999) J Biol Chem, 274, pp. 6935-6945Matsusaka, S., Nakasho, K., Terada, N., Sugihara, A., Tsujimura, T., Takanashi, T., Uematsu, K., Toyosaka, A., Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice (2000) Journal of Pediatric Surgery, 35 (8), pp. 1198-1204. , DOI 10.1053/jpsu.2000.8726Miele, C., Rochford, J.J., Filippa, N., Giorgetti-Peraldi, S., Van Obberghen, E., Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways (2000) Journal of Biological Chemistry, 275 (28), pp. 21695-21702. , DOI 10.1074/jbc.M000805200Miller, M.I., Puchner, P.J., Effects of finasteride on hematuria associated with benign prostatic hyperplasia: Long-term follow-up (1998) Urology, 51 (2), pp. 237-240. , DOI 10.1016/S0090-4295(97)00614-6, PII S0090429597006146Minischetti, M., Vacca, A., Ribatti, D., Iurlaro, M., Ria, R., Pellegrino, A., Gasparini, G., Dammacco, F., TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically (2000) British Journal of Haematology, 109 (4), pp. 829-837. , DOI 10.1046/j.1365-2141.2000.02087.xMontgomery, D.C., (1991) Design and Analysis of Experiments, 3rd Edn., , Wiley, New YorkMontico, F., Hetzl, A.C., Cândido, E.M., Fávaro, W.J., Cagnon, V.H., Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules (2011) Micron, 42, pp. 642-655Morrissey, C., Buser, A., Scolaro, J., O'Sullivan, J., Moquin, A., Tenniswood, M., Changes in hormone sensitivity in the ventral prostate of aging Sprague-Dawley rats (2002) Journal of Andrology, 23 (3), pp. 341-351Olumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., Tlsty, T.D., Cunha, G.R., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium (1999) Cancer Research, 59 (19), pp. 5002-5011Pandini, G., Genua, M., Frasca, F., Vigneri, R., Belfiore, A., Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway (2009) Ann N Y Acad Sci, 1155, pp. 263-267Pareek, G., Shevchuk, M., Armenakas, N.A., Vasjovic, L., Hochberg, D.A., Basillote, J.B., Fracchia, J.A., The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients (2003) Journal of Urology, 169 (1), pp. 20-23Plymate, S.R., Tennant, M.K., Culp, S.H., Woodke, L., Marcelli, M., Colman, I., Nelson, P.S., Ware, J.L., Androgen Receptor (AR) expression in AR-Negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors (2004) Prostate, 61 (3), pp. 276-290. , DOI 10.1002/pros.20099Prahalada, S., Rhodes, L., Grossman, S.J., Heggan, D., Keenan, K.P., Cukierski, M.A., Hoe, C.M., Van Zwieten, M.J., Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor (1998) Prostate, 35 (3), pp. 157-164. , DOI 10.1002/(SICI)1097-0045(19980515)35:3<157::AIDPrins, G.S., Jung, M.H., Vellanoweth, R.L., Chatterjee, B., Roy, A.K., Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia (1996) Developmental Genetics, 18 (2), pp. 99-106. , DOI 10.1002/(SICI)1520-6408(1996)18:2<99::AID-DVG2Retter, A.S., Figg, W.D., Dahut, W.L., The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer (2003) Clinical Prostate Cancer, 2 (3), pp. 153-159Reynolds, A.R., Kyprianou, N., Growth factor signalling in prostatic growth: Significance in tumour development and therapeutic targeting (2006) British Journal of Pharmacology, 147 (SUPPL. 2), pp. S144-S152. , DOI 10.1038/sj.bjp.0706635, PII 0706635Roy-Burman, P., Wu, H., Powell, W.C., Hagenkord, J., Cohen, M.B., Genetically defined mouse models that mimic natural aspects of human prostate cancer development (2004) Endocrine-Related Cancer, 11 (2), pp. 225-254. , DOI 10.1677/erc.0.0110225Rullis, I., Shaeffer, J.A., Lilien, O.M., Incidence of prostatic carcinoma in the elderly (1975) Urology, 6, pp. 295-297Ryan, C.J., Haqq, C.M., Simko, J., Nonaka, D.F., Chan, J.M., Weinberg, V., Small, E.J., Goldfine, I.D., Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer (2007) Urologic Oncology: Seminars and Original Investigations, 25 (2), pp. 134-140. , DOI 10.1016/j.urolonc.2006.07.019, PII S1078143906002419, Reconstructive Aspects of Urologic OncologySaikali, Z., Setya, H., Singh, G., Persad, S., Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells (2008) Cancer Cell Int, 8, p. 10Sin, N., Meng, L., Wang, M.Q.W., Wen, J.J., Bornmann, W.G., Crews, C.M., The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 (1997) Proceedings of the National Academy of Sciences of the United States of America, 94 (12), pp. 6099-6103. , DOI 10.1073/pnas.94.12.6099Sprenger, C.C., Plymate, S.R., Reed, M.J., Extracellular influences on tumour angiogenesis in the aged host (2008) British Journal of Cancer, 98 (2), pp. 250-255. , DOI 10.1038/sj.bjc.6604144, PII 6604144Strieth, S., Eichhorn, M.E., Sutter, A., Jonczyk, A., Berghaus, A., Dellian, M., Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo (2006) Int J Cancer, 119, pp. 423-431Sweeney, P., Karashima, T., Kim, S.-J., Kedar, D., Mian, B., Huang, S., Baker, C., Dinney, C.P.N., Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production (2002) Clinical Cancer Research, 8 (8), pp. 2714-2724Takamoto, T., Sasaki, M., Kuno, T., Tamaki, N., Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival (2001) Kobe Journal of Medical Sciences, 47 (4), pp. 181-191Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., Lieber, M.M., Coltman Jr., C.A., The influence of finasteride on the development of prostate cancer (2003) New England Journal of Medicine, 349 (3), pp. 215-224. , DOI 10.1056/NEJMoa030660Thum, T., Hoeber, S., Froese, S., Klink, I., Stichtenoth, D., Galuppo, P., Jakob, M., Bauersachs, J., Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone mediated increase of insulin-like growth factor-1 (2007) Circ Res, 100, pp. 434-443Tsukamoto, S., Akaza, H., Imada, S., Koiso, K., Shirai, T., Ideyama, Y., Kudo, M., Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex (1995) J Natl Cancer Inst, 87, pp. 842-843Turk, B.E., Griffith, E.C., Wolf, S., Biemann, K., Chang, Y.H., Liu, J.O., Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells (1999) Chem Biol, 6, pp. 823-833Tutrone Jr., R.F., Ball, R.A., Ornitz, D.M., Leder, P., Richie, J.P., Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model (1993) J Urol, 149, pp. 633-699Tuxhorn, J.A., Ayala, G.E., Rowley, D.R., Reactive stroma in prostate cancer progression (2001) Journal of Urology, 166 (6), pp. 2472-2483Tuxhorn, J.A., Ayala, G.E., Smith, M.J., Smith, V.C., Dang, T.D., Rowley, D.R., Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling (2002) Clinical Cancer Research, 8 (9), pp. 2912-2923Van Moorselaar, R.J.A., Voest, E.E., Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches (2002) Molecular and Cellular Endocrinology, 197 (1-2), pp. 239-250. , DOI 10.1016/S0303-7207(02)00262-9, PII S0303720702002629Wang, Y.Z., Wong, Y.C., Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer (1998) Prostate, 35 (3), pp. 165-177. , DOI 10.1002/(SICI)1097-0045(19980515)35:3<165::AIDYoshiji, H., Harris, S.R., Thorgeirsson, U.P., Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells (1997) Cancer Research, 57 (18), pp. 3924-3928Zar, J.H., (1999) Biostatistical Analysis, , Prentice Hall Upper, New Jerse